Five things for pharma marketers to know: Thursday, April 6, 2017
1. The FDA is quicker at approving drugs than the European Medicines Agency, with the median FDA review time for the approval of 142 drugs between 2011 and 2015 being 303 days, compared to 369 days by the EMA, a new analysis found. (Stat)
2. Allergan plans to move forward with Phase-III testing of Botox to treat depression, despite mixed results in a mid-stage trial. (Reuters)
3. GlaxoSmithKline will recall nearly 600,000 inhalers in the U.S. after discovering that they may dispense less medicine than expected. (Reuters)
4. FDA commissioner nominee Scott Gottlieb said the problem of expensive, brand-name drugs can be solved by faster approval of generic drugs and expanding the biosimilars market. (WSJ)
5. Takeda and Finch Therapeutics announced a collaboration to develop a synthetic microbiome therapy for inflammatory bowel disease. Takeda will pay Finch $10 million for exclusive worldwide rights to market the therapy FIN-524.